感染性疾病科住院成人综合征分子检测对抗菌药物处方的实际影响。呼吸道综合征分子检测小组：值得吗？

IF 2.9 4区医学 Q2 INFECTIOUS DISEASES

Infectious diseases now Pub Date : 2024-05-25 DOI:10.1016/j.idnow.2024.104933

Séverine Clauss , Stéphane Bourlet , Karim Jaffal , Clara Duran , Emma D’Anglejan , Véronique Perronne , Frédérique Bouchand , Latifa Noussair , Lotfi Dahmane , Aurélien Dinh

{"title":"感染性疾病科住院成人综合征分子检测对抗菌药物处方的实际影响。呼吸道综合征分子检测小组：值得吗？","authors":"Séverine Clauss , Stéphane Bourlet , Karim Jaffal , Clara Duran , Emma D’Anglejan , Véronique Perronne , Frédérique Bouchand , Latifa Noussair , Lotfi Dahmane , Aurélien Dinh","doi":"10.1016/j.idnow.2024.104933","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>While sensitive molecular diagnostic tests enable accurate and rapid diagnosis of many respiratory viruses, their impact on antibiotic management remains uncertain.</p><p>Our study aimed to evaluate the impact of respiratory syndromic molecular testing panel in real-life clinical practice.</p></div><div><h3>Method</h3><p>Retrospective descriptive study involving consecutive hospitalized patients in an infectious disease department who had been prescribed a respiratory syndromic molecular testing panel on nasopharyngeal swab samples (FilmArray Respiratory Panel 2 <em>plus</em>) during hospitalization from October 1st, 2021, to February 28th, 2023.</p></div><div><h3>Results</h3><p>All in all, 94 out of 210 screened patients were included in the study. Syndromic molecular testing results influenced antibiotic treatment in seven cases: discontinuation in four cases (three virus identifications), changes in two (<em>Mycoplasma pneumoniae</em> positive cases), and initiation in two (negative viral PCRs and one positive bacterial culture).</p></div><div><h3>Conclusion</h3><p>In our study, respiratory syndromic molecular testing had low impact on antibiotic modification.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 5","pages":"Article 104933"},"PeriodicalIF":2.9000,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000964/pdfft?md5=e3bd4b3981907961474bf2a31316175d&pid=1-s2.0-S2666991924000964-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Real-life impact on antimicrobial prescription of Syndromic Molecular Testing in adults hospitalized in infectious disease departments. Respiratory Syndromic Molecular Testing panel: Is it worth it?\",\"authors\":\"Séverine Clauss , Stéphane Bourlet , Karim Jaffal , Clara Duran , Emma D’Anglejan , Véronique Perronne , Frédérique Bouchand , Latifa Noussair , Lotfi Dahmane , Aurélien Dinh\",\"doi\":\"10.1016/j.idnow.2024.104933\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>While sensitive molecular diagnostic tests enable accurate and rapid diagnosis of many respiratory viruses, their impact on antibiotic management remains uncertain.</p><p>Our study aimed to evaluate the impact of respiratory syndromic molecular testing panel in real-life clinical practice.</p></div><div><h3>Method</h3><p>Retrospective descriptive study involving consecutive hospitalized patients in an infectious disease department who had been prescribed a respiratory syndromic molecular testing panel on nasopharyngeal swab samples (FilmArray Respiratory Panel 2 <em>plus</em>) during hospitalization from October 1st, 2021, to February 28th, 2023.</p></div><div><h3>Results</h3><p>All in all, 94 out of 210 screened patients were included in the study. Syndromic molecular testing results influenced antibiotic treatment in seven cases: discontinuation in four cases (three virus identifications), changes in two (<em>Mycoplasma pneumoniae</em> positive cases), and initiation in two (negative viral PCRs and one positive bacterial culture).</p></div><div><h3>Conclusion</h3><p>In our study, respiratory syndromic molecular testing had low impact on antibiotic modification.</p></div>\",\"PeriodicalId\":13539,\"journal\":{\"name\":\"Infectious diseases now\",\"volume\":\"54 5\",\"pages\":\"Article 104933\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-05-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666991924000964/pdfft?md5=e3bd4b3981907961474bf2a31316175d&pid=1-s2.0-S2666991924000964-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases now\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666991924000964\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991924000964","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

背景：虽然敏感的分子诊断检测能够准确、快速地诊断多种呼吸道病毒，但其对抗生素管理的影响仍不确定。我们的研究旨在评估呼吸道综合征分子检测小组在实际临床实践中的影响：方法：回顾性描述性研究，涉及 2021 年 10 月 1 日至 2023 年 2 月 28 日期间感染性疾病科连续住院患者，这些患者在住院期间接受了鼻咽拭子样本呼吸道综合征分子检测面板（FilmArray Respiratory Panel 2 plus）：总之，210 名接受筛查的患者中有 94 人被纳入研究。综合征分子检测结果影响了7例患者的抗生素治疗：4例停药（3例病毒鉴定），2例改药（肺炎支原体阳性病例），2例开始用药（病毒PCR阴性，1例细菌培养阳性）：结论：在我们的研究中，呼吸道综合征分子检测对抗生素调整的影响较小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-life impact on antimicrobial prescription of Syndromic Molecular Testing in adults hospitalized in infectious disease departments. Respiratory Syndromic Molecular Testing panel: Is it worth it?

Background

While sensitive molecular diagnostic tests enable accurate and rapid diagnosis of many respiratory viruses, their impact on antibiotic management remains uncertain.

Our study aimed to evaluate the impact of respiratory syndromic molecular testing panel in real-life clinical practice.

Method

Retrospective descriptive study involving consecutive hospitalized patients in an infectious disease department who had been prescribed a respiratory syndromic molecular testing panel on nasopharyngeal swab samples (FilmArray Respiratory Panel 2 plus) during hospitalization from October 1st, 2021, to February 28th, 2023.

Results

All in all, 94 out of 210 screened patients were included in the study. Syndromic molecular testing results influenced antibiotic treatment in seven cases: discontinuation in four cases (three virus identifications), changes in two (Mycoplasma pneumoniae positive cases), and initiation in two (negative viral PCRs and one positive bacterial culture).